ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

pfizer europe ma eeig - fesoterodinfumarat - urinblære, overaktiv - urologika - behandling av symptomene (økt urinfrekvens og / eller haster og / eller hasterinkontinens) som kan oppstå hos pasienter med overaktiv-blære syndrom.

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

medice arzneimittel pütter gmbh & co kg - deksamfetaminsulfat - tablett - 10 mg

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

medice arzneimittel pütter gmbh & co kg - deksamfetaminsulfat - tablett - 20 mg

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

boehringer ingelheim vetmedica gmbh - lawsonia intracellularis, levende svekkket - lyofilisat og væske til mikstur, suspensjon

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

chanelle pharmaceuticals manufacturing ltd - ivermektin - mikstur, oppløsning - 0.8 mg/ ml

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

aspen pharma trading limited - bupivakainhydroklorid - injeksjonsvæske, oppløsning - 2.5 mg/ ml

নরওয়ে - নরওয়েজীয় - Statens legemiddelverk

aspen pharma trading limited - bupivakainhydroklorid - injeksjonsvæske, oppløsning - 5 mg/ ml

ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - andre antineoplastiske midler - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

novartis europharm limited  - gozetotide - radionuklide bildebehandling - diagnostiske radiopharmaceuticals - dette legemidlet er kun til diagnostisk bruk. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.

ইউরোপীয় ইউনিয়ন - নরওয়েজীয় - EMA (European Medicines Agency)

bpl bioproducts laboratory gmbh - menneskelige koagulering faktor x - faktor x-mangel - vitamin k and other hemostatics, antihemorrhagics, coagulation factor x - coagadex er indisert for behandling og profylakse av blødningsepisoder og for perioperativ behandling hos pasienter med arvelig faktor x-mangel. coagadex er angitt i alle aldersgrupper.